OncoMethylome Presents Promising Results of Colorectal Cancer Screening Program

04-May-2010 - USA

OncoMethylome Sciences presented an update on its blood-based colorectal screening test and promising preliminary results of the performance of its proprietary DNA methylation biomarker in combination with stool-based testing at the Annual Digestive Disease Week (DDW) Conference.

"The combination of a DNA methylation biomarker with a commercially available fecal immunochemical test is showing excellent potential as a non-invasive and accurate screening test for colorectal cancer. In our study, the sensitivity and specificity of the combined test are both over 90% while also detecting a high percentage of early stage cancers" said Prof. Gerrit Meijer, from the VU University Medical Center in Amsterdam (VUMC), whose team conducted the latest case-control study using stool samples.

Dr. Jan Groen, Chief Executive Officer of OncoMethylome, said, "Our most recent case-control study in blood samples confirmed earlier results presented in September 2009 and we are delighted with the promising preliminary results in stool samples reported by the group at VUMC that constitute an independent validation of the clinical relevance of our proprietary methylation biomarker in colon cancer screening."

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance